CAMBRIDGE, England & BOSTON–(BUSINESS WIRE)–Bicycle
Therapeutics, a biotechnology company pioneering a new class of
therapeutics based on its proprietary bicyclic peptide (Bicycle®)
product platform, announced today that Paul Beswick, Ph.D., Bicycle’s
Director of UK Chemistry and IP, will present at the Research &
Innovation 2019 conference sponsored by the European Laboratory Research
& Innovation Group (ELRIG) in Cambridge, U.K. The presentation,
showcasing Bicycles as an entirely new class of therapeutics,
will take place on Wednesday, April 3, at 14:45 BST.
“Bicycles are a unique therapeutic modality, combining the pharmacology
usually associated with a biologic and the manufacturing and
pharmacokinetic properties of a small molecule,” said Nicholas Keen,
Ph.D., Chief Scientific Officer of Bicycle Therapeutics. “Our technology
has great potential both in the field of oncology and more broadly, and
we’re excited to share our work at this ELRIG conference.”
About Bicycle Therapeutics
Bicycle Therapeutics is developing a unique class of chemically
synthesised medicines based on its proprietary bicyclic peptide (Bicycle®)
product platform to address therapeutic needs unreachable with existing
treatment modalities. Bicycle’s internal focus is in oncology, where the
company is developing targeted cytotoxics (Bicycle Toxin Conjugates®),
targeted innate immune activators and T-cell modulators for cancers of
high unmet medical need. Bicycles’ small size and
highly selective targeting deliver rapid tumour penetration and
retention while clearance rates and routes of elimination can be tuned
to minimise exposure of healthy tissue and bystander toxicities. The
company’s lead program, BT1718, is being evaluated in a Phase I/IIa
trial in collaboration with Cancer Research UK. The company’s unique
intellectual property is based on the work initiated at the MRC
Laboratory of Molecular Biology in Cambridge, U.K., by the scientific
founders of the company, Sir Greg Winter, a winner of the Nobel Prize in
Chemistry for his pioneering work in phage display of
peptides and antibodies, and Professor Christian Heinis. Bicycle has its
headquarters in Cambridge, U.K., with many key functions and members of
its leadership team located in the biotech hub of Boston, Mass. For more
information, visit www.bicycletherapeutics.com or
follow us on Twitter at @Bicycle_tx.
Contacts
Media:
Ten Bridge Communications
Sara Green
sgreen@tenbridgecommunications.com
+1-617-233-1714
Investors:
Argot
Partners
Maeve Conneighton
maeve@argotpartners.com
+1-212-600-1902